Search

Your search keyword '"Brune, Mats"' showing total 430 results
Start Over Author "Brune, Mats"
430 results on '"Brune, Mats"'

1. Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50–70 year old AML patients

Author

Brune, Mats, Kiss, Thomas, Anderson, Harald, Nicklasson, Malin, Delage, Robert, Finke, Jürgen, Gedde-Dahl, Tobias, Hébert, Josée, Höglund, Martin, Kaare, Ain, Lazarevic, Vladimir, Möllgård, Lars, Remes, Kari, Ritchie, David, Spyridonidis, Alexandros, Sabloff, Mitchell, Spearing, Ruth, Wallhult, Elisabeth, and Ljungman, Per

Published
2024
Full Text
View/download PDF

3. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity

Author

Einarsdottir, Sigrun, Martner, Anna, Waldenström, Jesper, Nicklasson, Malin, Ringlander, Johan, Arabpour, Mohammad, Törnell, Andreas, Wiktorin, Hanna Grauers, Nilsson, Staffan, Bittar, Rudy, Nilsson, Malin, Lisak, Mikael, Veje, Malin, Friman, Vanda, Al-Dury, Samer, Bergström, Tomas, Ljungman, Per, Brune, Mats, Hellstrand, Kristoffer, and Lagging, Martin

Published
2022
Full Text
View/download PDF

7. A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study

Author

Chiusolo, Patrizia, Bug, Gesine, Olivieri, Attilio, Brune, Mats, Mordini, Nicola, Alessandrino, Paolo Emilio, Dominietto, Alida, Raiola, Anna Maria, Di Grazia, Carmen, Gualandi, Francesca, Van Lint, Maria Teresa, Ferrara, Felicetto, Finizio, Olimpia, Angelucci, Emanuele, and Bacigalupo, Andrea

Published
2018
Full Text
View/download PDF

10. Data from Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia

Author

Bernson, Elin, primary, Hallner, Alexander, primary, Sander, Frida E., primary, Nicklasson, Malin, primary, Nilsson, Malin S., primary, Christenson, Karin, primary, Aydin, Ebru, primary, Liljeqvist, Jan-Åke, primary, Brune, Mats, primary, Foà, Robin, primary, Aurelius, Johan, primary, Martner, Anna, primary, Hellstrand, Kristoffer, primary, and Thorén, Fredrik B., primary

Published
2023
Full Text
View/download PDF

11. Supplementary information from Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia

Author

Bernson, Elin, primary, Hallner, Alexander, primary, Sander, Frida E., primary, Nicklasson, Malin, primary, Nilsson, Malin S., primary, Christenson, Karin, primary, Aydin, Ebru, primary, Liljeqvist, Jan-Åke, primary, Brune, Mats, primary, Foà, Robin, primary, Aurelius, Johan, primary, Martner, Anna, primary, Hellstrand, Kristoffer, primary, and Thorén, Fredrik B., primary

Published
2023
Full Text
View/download PDF

16. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Author

Höglund, Martin, Sandin, Fredrik, Hellström, Karin, Björeman, Mats, Björkholm, Magnus, Brune, Mats, Dreimane, Arta, Ekblom, Marja, Lehmann, Sören, Ljungman, Per, Malm, Claes, Markevärn, Berit, Myhr-Eriksson, Kristina, Ohm, Lotta, Olsson-Strömberg, Ulla, Själander, Anders, Wadenvik, Hans, Simonsson, Bengt, Stenke, Leif, and Richter, Johan

Published
2013
Full Text
View/download PDF

19. High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry

Author

Mounier, Nicolas, Canals, Carmen, Gisselbrecht, Christian, Cornelissen, Jan, Foa, Roberto, Conde, Eulogio, Maertens, John, Attal, Michel, Rambaldi, Alessandro, Crawley, Charles, Luan, Jian-Jian, Brune, Mats, Wittnebel, Sebastian, Cook, Gordon, van Imhoff, G.W., Pfreundschuh, Michael, and Sureda, Anna

Published
2012
Full Text
View/download PDF

20. Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation

Author

Einarsdottir, Sigrun, primary, Martner, Anna, additional, Nicklasson, Malin, additional, Wiktorin, Hanna Grauers, additional, Arabpour, Mohammad, additional, Törnell, Andreas, additional, Vaht, Krista, additional, Waldenström, Jesper, additional, Ringlander, Johan, additional, Bergström, Tomas, additional, Brune, Mats, additional, Hellstrand, Kristoffer, additional, Ljungman, Per, additional, and Lagging, Martin, additional

Published
2022
Full Text
View/download PDF

22. Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse‐preventive immunotherapy in acute myeloid leukaemia

Author

Nilsson, Malin S., Hallner, Alexander, Brune, Mats, Nilsson, Staffan, Thorén, Fredrik B., Martner, Anna, and Hellstrand, Kristoffer

Subjects
Adult, Aged, 80 and over, Male, Adolescent, Induction Chemotherapy, Middle Aged, chemotherapy, Disease-Free Survival, Survival Rate, Leukemia, Myeloid, Acute, aml, Recurrence, Correspondence, IL‐2, histamine dihydrochloride, Humans, Female, Immunotherapy, Aged
Published
2019

23. Bone marrow expression of CD68/CD163 macrophages, IL‐17 and FOXP3 cells in aplastic anemia and their relation to prognosis.

Author

Vaht, Krista, Brenner, Jonas, Ednersson, Susanne Bram, Ljungman, Per, Brune, Mats, and Andersson, Per‐Ola

Subjects
BONE marrow, APLASTIC anemia, BONE marrow cells, REGULATORY T cells, T helper cells, PAROXYSMAL hemoglobinuria
Abstract

Objectives: The primary mechanism for bone marrow failure in aplastic anemia (AA) is autoimmune hematopoietic stem cell destruction. AA can be cured with antithymocyte globulin (ATG) treatment, and some smaller studies have indicated that the number of regulatory T cells (Tregs) may be predictive of response. Additionally, AA patients appear to have elevated numbers of Th17 cells and bone marrow macrophages, but outcome data are missing. Methods: We performed immunohistochemistry on bone marrow biopsies from 121 ATG‐treated AA patients and 14 healthy controls, using antibodies against FOXP3 (for Tregs), IL‐17 (for Th17), CD68 (for pan‐macrophages) and CD163 (for M2 type macrophages) to study their possible relation to ATG response and AA prognosis. Results: AA patients had significantly fewer Tregs and Th17 cells but significantly more macrophages compared with controls. Treg, Th17 and pan‐macrophage cell numbers were not associated with ATG response or differences in survival. Patients with higher levels of M2 macrophages had improved 5‐year overall survival: 79.6% versus 57.4% (p =.017), and this benefit was primarily seen in AA patients with non‐severe disease. Conclusions: We found that Treg and Th17 cell numbers did not predict ATG response or survival, whereas M2 macrophages may be associated with improved survival. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita

Author

Julián Sevilla, Paul Veys, E T Korthof, Régis Peffault de Latour, Dorine Bresters, Tracey A. O'Brien, Marco Zecca, Maura Faraci, Simona Iacobelli, Jean Hugues Dalle, Antonio M. Risitano, Luca Arcuri, Maurizio Miano, Francesca Fioredda, Ardeshir Ghavamzadeh, Reuven Or, Miguel Angel Diaz, Brune Mats, E V Skorobogatova, Josue de la Fuente, Cora Knol, Petr Sedlacek, Franca Fagioli, Cristina Díaz de Heredia, Ayami Yoshimi, Michael Maschan, Jakub Tolar, Owen P. Smith, Carlo Dufour, Mahmoud Aljurf, Maria Teresa Van Lint, Alain Fisher, Anja van Biezen, Fioredda, Francesca, Iacobelli, Simona, Korthof, Elisabeth T., Knol, Cora, van Biezen, Anja, Bresters, Dorine, Veys, Paul, Yoshimi, Ayami, Fagioli, Franca, Mats, Brune, Zecca, Marco, Faraci, Maura, Miano, Maurizio, Arcuri, Luca, Maschan, Michael, O'Brien, Tracey, Diaz, Miguel A., Sevilla, Julian, Smith, Owen, Peffault de Latour, Regi, de la Fuente, Josue, Or, Reuven, Van Lint, Maria T., Tolar, Jakub, Aljurf, Mahmoud, Fisher, Alain, Skorobogatova, Elena V., Diaz de Heredia, Cristina, Risitano, Antonio, Dalle, Jean-Hugue, Sedláček, Petr, Ghavamzadeh, Ardeshir, and Dufour, Carlo

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Transplantation Conditioning, Pulmonary Fibrosis, haematopoietic stem cell transplantation, Graft vs Host Disease, Disease, dyskeratosis congenita, Settore MED/01 - Statistica Medica, Young Adult, bone marrow failure, Hematology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Bone Marrow Diseases, business.industry, Age Factors, Hematopoietic Stem Cell Transplantation, Bone marrow failure, medicine.disease, Survival Analysis, Tissue Donors, Transplantation, Haematopoiesis, Treatment Outcome, surgical procedures, operative, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, Bone marrow, Stem cell, business, Dyskeratosis congenita, 030215 immunology
Abstract

Dyskeratosis congenita (DC) is a genetic multisystem disorder with frequent involvement of the bone marrow. Haematopoietic stem cell transplantation (HSCT) is the only definitive cure to restore haematopoiesis, even though it cannot correct other organ dysfunctions. We collected data on the outcome of HSCT in the largest cohort of DC (n = 94) patients ever studied. Overall survival (OS) and event-free survival (EFS) at 3 years after HSCT were 66% and 62%, respectively. Multivariate analysis showed better outcomes in patients aged less than 20 years and in patients transplanted from a matched, rather than a mismatched, donor. OS and EFS curves tended to decline over time. Early lethal events were infections, whereas organ damage and secondary malignancies appeared afterwards, even a decade after HSCT. A non-myeloablative conditioning regimen appeared to be most advisable. Organ impairment present before HSCT seemed to favour the development of chronic graft-versus-host disease and T-B immune deficiency appeared to enhance pulmonary fibrosis. According to the present data, HSCT in DC is indicated in cases of progressive marrow failure, whereas in patients with pre-existing organ damage, this should be carefully evaluated. Further efforts to investigate treatment alternatives to HSCT should be encouraged.

Published
2018
Full Text
View/download PDF

29. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

Author

Brune, Mats, Castaigne, Sylvie, Catalano, John, Gehlsen, Kurt, Ho, Anthony D., Hofmann, Wolf-Karsten, Hogge, Donna E., Nilsson, Bo, Or, Reuven, Romero, Ana I., Rowe, Jacob M., Simonsson, Bengt, Spearing, Ruth, Stadtmauer, Edward A., Szer, Jeff, Wallhult, Elisabeth, and Hellstrand, Kristoffer

Published
2006
Full Text
View/download PDF

30. Vaccination against tick-borne encephalitis (TBE) after autologous and allogeneic stem cell transplantation

Author

Einarsdottir, Sigrun, primary, Nicklasson, Malin, additional, Veje, Malin, additional, Bergström, Tomas, additional, Studahl, Marie, additional, Lisak, Mikael, additional, Olsson, Mikael, additional, Johansson, Berit, additional, Andreasson, Björn, additional, Piauger, Bénédicte, additional, Roth, Anette, additional, Friman, Vanda, additional, Ljungman, Per, additional, and Brune, Mats, additional

Published
2021
Full Text
View/download PDF

32. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: Real-World Population-Based Data From the Swedish Acute Leukemia Registry 1997-2006

Author

Juliusson, Gunnar, Karlsson, Karin, Lazarevic, Vladimir Lj, Wahlin, Anders, Brune, Mats, Antunovic, Petar, Derolf, Åsa, Hägglund, Hans, Karbach, Holger, Lehmann, Sören, Möllgård, Lars, Stockelberg, Dick, Hallböök, Helene, and Höglund, Martin

Published
2011
Full Text
View/download PDF

37. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT

Author

Crawley, Charles, Szydlo, Richard, Lalancette, Marc, Bacigalupo, Andrea, Lange, Andrzej, Brune, Mats, Juliusson, Gunnar, Nagler, Arnon, Gratwohl, Alois, Passweg, Jakob, Komarnicki, Mieczysław, Vitek, Antonin, Mayer, Jiri, Zander, Axel, Sierra, Jorge, Rambaldi, Alessandro, Ringden, Olle, Niederwieser, Dietger, and Apperley, Jane F.

Published
2005
Full Text
View/download PDF

39. Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)

Author

Garderet, Laurent, Labopin, Myriam, Gorin, Norbert-Claude, Polge, Emmanuelle, Baruchel, André, Meloni, Giovanna, Ortega, Juan, Vossen, Jaak, Bunjes, Donald, Leverger, Guy, Blaise, Didier, Ferrant, Augustin, Brune, Mats, Dore, Eric, Gadner, Helmut, Zintl, Felix, Yaniv, Isaac, Dini, Giorgio, and Frassoni, Francesco

Published
2005
Full Text
View/download PDF

44. Late follow‐up of genital and ophthalmologic chronic graft‐vs‐host disease in females after allogeneic stem cell transplantation.

Author

Smith Knutsson, Eva, Nicklasson, Malin, Björk, Yvonne, Stenberg, Kristina, Sundfeldt, Karin, and Brune, Mats

Subjects
STEM cell transplantation, PAPILLOMAVIRUSES, CHRONIC diseases, MUCOUS membranes, VULVAR cancer, SYMPTOMS
Abstract

Introduction: Genital chronic graft‐vs‐host disease (cGvHD) is a common late effect after allogeneic stem cell transplantation. In a previous cross‐sectional study, prevalence, signs and symptoms of genital and extra‐genital cGvHD were accounted for in a cohort of 42 women. Classifications of cGvHD were performed as per the National Institutes of Health (NIH) 2005 criteria. In this follow‐up study on surviving women, the aim was to assess genital and extra‐genital cGvHD status after long period of time. Our hypothesis was that signs and symptoms of cGvHD alleviate over time. Material and methods: All surviving women (n = 38) were re‐examined by an ophthalmologist, a gynecologist and a hematologist. Signs and symptoms were classified according to the NIH 2014 criteria. Clinical scorings of affected organs were combined for estimating global score of cGvHD. To make possible comparisons between the two studies, data from the original study were re‐classified as per the NIH 2014 criteria, and the four dead women were excluded. The same questionnaires were completed. Cervical smear, human papilloma virus test and vulvar photo‐documentation were performed. Results: Median time after original study was 8.4 (5.8–12) years and after transplant 14.5 (10–19.3) years. The prevalence of genital cGvHD was similar in the original (50%) and follow‐up (58%) studies (p = 0.646) as well as extra‐genital cGvHD. Systemic corticosteroid treatment of cGvHD was ongoing in 34% and 29%, respectively (p = 0.805). Ocular cGvHD was found in 24 of 37 examined women (65%) in the follow‐up study. Genital cGvHD had disappeared in three women and developed in two women 5–12 and 9–17 years, respectively, after transplantation. The severity of global cGvHD changed over time in 14 women, but was the same on group level (p = 0.345). Atrophic mucous membranes as in estrogen deficiency were seen in 66%. Three women had human papilloma virus genotypes associated with the risk of developing cervical cancer. Conclusions: Chronic GvHD did not alleviate over time. Allotransplanted women require early and continuous life‐long contact with a gynecologist and an ophthalmologist for the detection of cGvHD. Specific attention should be given to the need for local estrogen and the risk of genital epithelial malignancies. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Iron absorption from bread in humans: inhibiting effects of cereal fiber, phytate and inositol phosphates with different numbers of phosphate groups

Author

Brune, Mats, Rossander-Hulten, Lena, Hallberg, Leif, Gleerup, Ann, and Sandberg, Ann-Sofie

Subjects
Bread -- Health aspects, Food -- Iron content, Absorption (Physiology) -- Research, Food/cooking/nutrition
Abstract

Absorption of iron from five kinds of bread with different fiber and inositol phosphate contents was measured using two radioiron tracers. Inhibition of iron absorption was shown in breads with high inositol hexaphosphate content. On the other hand, bread made from fermented dough was shown to have reduced phytate content and was proven to increase iron absorption. This indicates that suppression of iron bioavailability in bran-rich bread arises from its high inositol phosphate content and not from its fiber composition.

Published
1992

50. Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia

Author

Brune Mats L, Lucchesi Kathryn J, Squifflet Pierre, Buyse Marc, Castaigne Sylvie, and Rowe Jacob M

Subjects
Medicine (General), R5-920
Abstract

Abstract Background Data from a randomized multinational phase 3 trial of 320 adults with acute myeloid leukemia (AML) demonstrated that maintenance therapy with 3-week cycles of histamine dihydrochloride plus low-dose interleukin-2 (HDC/IL-2) for up to 18 months significantly improved leukemia-free survival (LFS) but lacked power to detect an overall survival (OS) difference. Purpose To assess the consistency of treatment benefit across patient subsets and the robustness of data with respect to trial centers and endpoints. Methods Forest plots were constructed with hazard ratios (HRs) of HDC/IL-2 treatment effects versus no treatment (control) for prospectively defined patient subsets. Inconsistency coefficients (I2) and interaction tests (X2) were used to detect any differences in benefit among subsets. Robustness of results to the elimination of individual study centers was performed using "leave-one-center-out" analyses. Associations between treatment effects on the endpoints were evaluated using weighted linear regression between HRs for LFS and OS estimated within countries. Results The benefit of HDC/IL-2 over controls was statistically consistent across all subsets defined by baseline prognostic variables. I2 and P-values of X2 ranged from 0.00 to 0.51 and 0.14 to 0.91, respectively. Treatment effects were statistically significant in 14 of 28 subsets analyzed. The "leave-one-center-out" analysis confirmed that no single center dominated (P-values ranged from 0.004 to 0.020 [mean 0.009]). The HRs representing the HDC/IL-2 effects on LFS and OS were strongly correlated at the country level (R2 = 0.84). Limitations Small sample sizes in some of the subsets analyzed. Conclusions These analyses confirm the consistency and robustness of the HDC/IL-2 effect as compared with no treatment. LFS may be an acceptable surrogate for OS in future AML trials. Analyses of consistency and robustness may aid interpretation of data from multicenter trials, especially in populations with rare diseases, when the size of randomized clinical trials is limited. Trial Registration ClinicalTrials.gov: NCT00003991

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results